

30 March 2022

Incidence and Treatment of Different Types of Cancer in Belfast Trust in the past 3 months from 10/03/2022

1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:

• Carboplatin (monotherapy or in combination with 5-FU)	<5
• Cisplatin (monotherapy or in combination with 5-FU)	19
• Cetuximab with/without chemotherapy	
• Cetuximab with radiotherapy	
• Pembrolizumab monotherapy	9
• Pembrolizumab with chemotherapy	
• Nivolumab	<5
• Docetaxel (monotherapy or in combination with 5-FU)	
• Fluorouracil (5FU)	
• Radiotherapy only	52
• Other: Etoposide and Carboplatin AUC6	<5
Gemcitabine and Cisplatin	<5
Paclitaxel/Carboplatin	<5
Paclitaxel	<5

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:

- Total number of head and neck cancer patients - 41 + 52 (Radiotherapy)
- Number of locally advanced head and neck cancer patients
- Number of recurrent and/or metastatic head and neck cancer patients

3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:

• Atezolizumab	<5
• Carboplatin with Gemcitabine	
• Carboplatin single or in any other combination	
• Cisplatin with Gemcitabine	5
• Cisplatin single or in any other combination	
• Nivolumab	
• Pembrolizumab	
• Any other regimen including Paclitaxel	

30 March 2022

- Any other chemotherapy regimen
- Other active systemic anti-cancer therapy [please state]
- Palliative care only

4. Does your Trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial, along with the number of patients taking part?

MK3475-045: A Phase III randomised clinical trial of MK-3475 versus Paclitaxel, Docetaxel or Vinflunine in subjects with recurrent or progressive metastatic urothelial cancer. This study has now closed to recruitment, having recruited two patients. One patient continues on follow-up in the extension study: **MK3475-587** (A multi-centre, open label, Phase III extension trial to study the long-term safety and efficacy in participants with advanced tumours who are currently on treatment or in follow-up in a Pembrolizumab Trial).

IMvigor011: A Phase III, double-blind, multi-centre randomized study of Atezolizumab (anti-PDL1 antibody) versus placebo as adjuvant therapy in patients with high-risk muscle-invasive bladder cancer who are circulating tumour DNA (ctDNA) positive following cystectomy. This study opened to recruitment on 7 March 2022 and has yet to recruit.

The following study is currently in set-up:

RE-ARM: A randomised Phase II trial of enhancement of efficacy of Atezolizumab by Radiotherapy in metastatic urothelial carcinoma